Document:

EX-10.2

 Exhibit 10.2 

Amendment 
 THIS AMENDMENT is made
as of the 9th day of November, 2009 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, with its head office at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (hereinafter called “TAKEDA”) and
Tobira Therapeutics, Inc., with its principal office at 214 Carnegie Center, Suite 306, Princeton, NJ 08540 USA (hereinafter called “TOBIRA”), 

WITNESSETH THAT: 
 WHEREAS, TAKEDA and
TOBIRA executed a certain License Agreement between the parties as of August 1, 2007, under which Tobira has been developing certain CCR5 antagonists (hereinafter called the “Agreement”): 

WHEREAS, TOBIRA desires to receive transfer from TAKEDA of and TAKEDA is willing to transfer to TOBIRA certain patent(s) under the terms and conditions
contained herein: 
 NOW THEREFORE, the parties hereto agree as follows: 
  

	1.	Certain patent(s) shall be transferred from TAKEDA to TOBIRA and therefore, such patent(s) shall be added to and treated as the Assigned Patents in accordance with the provisions of the Agreement, including without
limitation Article 3.0 and 13. 

 Schedule 1(5) and Schedule 2.B. of the Agreement shall be replaced with the patent list
attached hereto as Schedule 1(5) and Schedule 2.B. to reflect such addition. 
  

	2.	Details of such patent transfer (including without limitation the TOBIRA’s obligation to reimuburse TAKEDA the patent assignment cost as well as the patent division cost incurred for the patent division made by
TAKEDA prior to and in relating to such patent transfer) shall be separately determined by the parties and, notwithstanding the provision of above Item 1, Article 3.A and 3.B of the Agreement shall not apply for such transfer hereunder.

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 1 

	3.	This Amendment shall be in effect as from the Effective Date and shall be in effect as long as the Agreement is in effect. In case the Agreement is terminated for any reason, this Amendment shall automatically be
terminated at the same time. 

  

	4.	Except as expressly set forth in this Amendment, the Agreement shall not be changed and shall remain in full force and be ratified and confirmed in its entity. 

IN WITNESS WHEREOF, the Parties have caused this Amendment to be executed by their duly authorized officers in duplicate as of the day and year first
above written. One each text of this Agreement shall be held by either Party hereto. 
  

			
	TAKEDA PHARMACEUTICAL COMPANY LIMITED
	
	 [*]

	Name:		[*]
	Title:		[*]
	
	TOBIRA THERAPEUTICS, INC.
	
	 [*]

	Name:		[*]
	Title:		[*]

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 2 

 Schedule 1(5) – Assigned Patents 

Assigned Patents: 
  

	(a)	Principal Compound 

  

							
	 Takeda’s

Case No.
	 	 Country
	 	 Application No.

(Filing date)
	 	 Patent No.

(Issue date)

	[*]	 	[*]	 	[*]	 	[*]

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 3 

	(b)	Reserve Compound 

  

							
	 Takeda’s

Case No.
	 	 Country
	 	 Application

(Filing date)
	 	 Patent No.

(Issue date)

	[*]	 	[*]	 	[*]	 	[*]

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 4 

 Schedule 2. B. – Ancillary Patents 

Ancillary Patents: 
 (a) Principal
Compound 
  

							
	 Takeda’s Case No.
	 	 Country
	 	 Application

(Filing date)
	 	 Patent No.

(Issue date)

	[*]	 	[*]	 	[*]	 	[*]

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 5 

 (b) Reserve Compound 
  

							
	 Takeda’s Case No.
	 	 Country
	 	 Application

(Filing date)
	 	 Patent No.

(Issue date)

	[*]	 	[*]	 	[*]	 	[*]

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions. 
  
 6 

 

 
 [*] 

  
 Confidential 

[*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been
requested with respect to the omitted portions.EXHIBIT 10.1

Midam Ventures, LLC

ENGAGEMENT LETTER

June 17, 2015

 

VIA EMAIL/FAX/REGULAR MAIL

Robert Sand,CEO

FBEC Worldwide Inc.

1621 Central Ave

Cheyenne, WY 95975

 

Dear Mr. Sand,

 

I am very pleased that you have selected
Midam Ventures, LLC (hereinafter “Midam”) to act as an advisor and consultant to FBEC Worldwide, Inc. (the “Company”)
(hereinafter collectively referred to as the “Parties”), and I look forward to working with you and your team to accomplish
your goals. This Engagement Letter (the “Agreement”) shall confirm the Company’s engagement of MIDAM for purposes
of providing business advisory services as set forth below in consideration for the fees and compensation described hereinafter.
This Agreement shall become effective as of the date set forth above upon your execution and delivery of this Agreement and the
engagement fee to MIDAM.

 

Recital: The Company agrees to provide
MIDAM, on a regular and timely basis, such information, historical financial data, projections, Performa’s, business plans,
due diligence documentation, and other information (collectively the “Information”) in the possession of the Company
or its agents that MIDAM may reasonably request or require to perform the services set forth herein. The information provided by
the Company to MIDAM shall be true, complete, accurate, and current in all respects and shall not set forth any untrue statements
nor omit any fact required or necessary to make the Information provided not misleading. The Company shall be deemed to make a
continuing representation of the accuracy and completeness of any and all Information that it supplies to MIDAM and the Company
acknowledges that it intends for MIDAM to rely on this representation and the continued accuracy and completeness of the Information
without independent verification in the performance of the Services hereunder. The Company authorizes MIDAM to use such Information
in connection with its performance of the Services. MIDAM shall use its best efforts to preserve the confidentiality of Information
expressly designated as confidential by the Company. The Company shall promptly and in a timely manner respond to the request(s)
of MIDAM regarding specific Information and assistance. MIDAM understands that from time to time they will need to work with the
Company’s IR consultant, Lamina International and John Mattio.

 

 

    	1

    	 

    

 

 

Services. MIDAM will provide
the Company with various business advisory and consulting services as referenced in Exhibit-A attached hereof for the purpose of
creating market awareness under SEC and OTC Guidelines and regulations, further referred to as (the ”Services”). The
Company acknowledges that the results of said Services would dependent upon various factors and circumstances outside the control
of MIDAM. The Company acknowledges that MIDAM has not made any representations, warranties or guarantees that the Services to be
provided hereunder shall result in (a) the purchase of the Company’s securities by any investors; (b) funds being made available
to the Company from any lenders; (c) any financing vehicles being made available to the Company; (d) any merger, acquisition or
disposition in connection with the business or assets of the Company, or any financing transaction (whether registered with the
U.S. Securities and Exchange Commission or pursuant to an exemption from such registration) involving the Company will take place;
(e) the Company or its successors becoming a “publicly traded” company inside or outside of the United States; or (f)
the achievement of any particular result with respect to the Company’s business, stock price, trading volume, market capitalization
or otherwise.

 

License of Trademark: In addition
to the Services described above and in Exhibit A, MIDAM will grant a license (the “License”) to the Company for the
use of the “Wolfshot” Trademark, in connection with an energy drink to be produced by the Company. The License shall
last for the term of this Agreement and any renewals or extensions hereto. Each party shall at any time or times hereafter make,
execute and deliver any and all documents, instruments, assurances and things as may reasonably be required for the purpose of
giving full force and effect to this Agreement and the covenants, conditions and provisions of this Agreement, without charge to
the other party, including but not limited to a Trademark License Agreement.

 

Consulting Fee. In addition
to and not in mitigation of, or substitution for, any additional fees enumerated in any Schedules attached hereto, the Company
shall issue to Midam Venture LLC consideration of Ten Million (10,000,000) restricted common shares as consideration for the term
of this Engagement. The shares will be issued in 10 equal monthly installment commencing on the date of this agreement and each
thirty (30) days thereafter.

 

Term and Termination. The
term of this Agreement shall be for ten (10) Months beginning on June 17, 2015 and ending on April 16, 2016. Either Party may terminate
this Agreement prior to the expiration of the Term upon written notice to the non-terminating party upon: (a) the failure of any
party to cure a material default under this Agreement within five (5) business days after receiving written notice of such default
from the terminating party; (b) the bankruptcy or liquidation of either party; (c) the use by any party of any insolvency laws;
(d) the performance of the Services hereunder; and (e) the appointment of a receiver for all or a substantial portion of either
parties’ assets or business. If terminated, irrespective of the reasons for such termination, MIDAM shall not be required
to perform any additional services beyond the termination date and all fees described in this Agreement shall be deemed earned
in full.

 

Relationship of the Parties. MIDAM
is an independent contractor, responsible for compensation of its agents, employees and representatives, as well as all applicable
withholding there from and any taxes thereon (including any unemployment compensation) and all workers’ compensation insurance.
Nothing herein shall establish any partnership, joint venture, or other business association between the parties.

 

 

    	2

    	 

    

 

Disputes. Any dispute, controversy
or claim between the Company and MIDAM arising out of or related to this Agreement or breach thereof, except those faults described
in the Remedies for Certain Faults section of this Agreement, shall be settled by arbitration, which shall be conducted in accordance
with the rules of the American Arbitration Association then in effect and conducted in the County of Miami-Dade in the State of
Florida. Any award made by arbitrators shall be binding and conclusive for all purposes thereof, may include injunctive relief,
as well as orders for specific performance and may be entered as a final judgment in any court of competent jurisdiction. The cost
and expenses of such arbitration shall be borne in accordance with the determination of the arbitrators and may include reasonable
attorney’s fees. Each party hereby further agrees that service of process may be made upon it by registered or certified
mail or personal service at the address provided herein.

 

Indemnification by COMPANY to MIDAM.
The Company shall indemnify and hold harmless MIDAM and its directors, officers, employees, agents, attorneys and assigns
from and against any and all losses, claims, costs, damages, or liabilities (including the fees and expenses of legal counsel)
to which any of them may become subject in connection with the investigation, defense or settlement of any actions or claims: (i)caused
by the Company’s misstatement or alleged misstatement of a material fact or omission or alleged omission of a material fact
required to make any statement not misleading; (ii) arising in any manner out of or in connection with the rendering of Services
by MIDAM hereunder; or (iii) otherwise in connection with this Agreement. The Company shall not be liable for any settlement of
any action effected without its written consent.

 

Notices. All notices hereunder
shall be in writing and shall be validly given, made or served if in writing and delivered in person or when received by facsimile
transmission, or five days after being sent first class certified or registered mail, postage prepaid, or one day after being sent
by a nationally recognized overnight carrier to the party for whom intended at the address set forth after each parties signatures.

 

Severability. If any clause
or provision of the Agreement is illegal, invalid or unenforceable under applicable present or future laws effective during the
Term, the remainder of this Agreement shall not be affected. In lieu of each clause or provision of this Agreement, that is illegal,
invalid or unenforceable, there shall be added as a part of this Agreement a clause or provision as nearly identical as may be
possible, and as may be legal, valid, and enforceable. In the event that any clause or provision of this Agreement is illegal,
invalid, or unenforceable as aforesaid and the effect of such illegality, invalidity, or unenforceability is that either party
no longer has the substantial benefit of its bargain under this Agreement and a clause or provision as nearly identical as may
be possible cannot be added, then, in such event, such party may in its discretion cancel and terminate this Agreement provided
such party exercises such right within a reasonable time after such occurrence.

 

This is our Agreement. The
parties agree and acknowledge that they have jointly participated in the negotiation and drafting of this Agreement and that this
Agreement has been fully reviewed and negotiated by the parties and their respective counsel. In the event of an ambiguity or question
of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties and no presumptions
or burdens of proof shall arise favoring any party by virtue of the authorship of any of the provisions of this Agreement.

 

Governing Law. This Agreement
shall be governed by and construed under the laws of the State of Florida without regard to principals of conflicts of laws provisions.

 

Venue. Venue for any dispute
arising out of this Agreement shall be in a court of competent jurisdiction in Miami-Dade County, Florida.

 

Interpretation. The
Parties hereby acknowledge and agree that each has participated in the negotiation and drafting of this Agreement and that the
principle of construing a document most strictly against its drafter shall not apply with respect to the interpretation of this
agreement.

 

Paragraph Headings. Headings
in this Agreement are for reference purposes only and shalt not be deemed to have any substantive effect.

 

 

    	3

    	 

    

 

Amendments and Waivers. This
Agreement may not be modified, amended, supplemented, canceled or discharged, except by written instrument executed by all parties.
No failure to exercise, and no delay in exercising, any right, power or privilege under this Agreement shall operate as a waiver,
nor shall any single or partial exercise of any right, power or privilege hereunder preclude the exercise of any other right, power,
or privilege. No waiver of any breach of any provision shall be deemed to be a waiver of any preceding or succeeding breach of
the same or any other provision, nor shall any waiver be implied from any course of dealing between the parties. To be effective,
all waivers must be in writing, signed by both parties. The rights and remedies of the parties under this Agreement are in addition
to all other rights and remedies, at law or equity, that they may have against each other except as may be specifically limited
herein.

 

This is our entire Agreement. This
Agreement contains the entire understanding of the parties in respect of its subject matter and supersedes all prior agreements
and understandings (oral and written) between or among the parties with respect to such subject matter. The parties agree that
prior drafts of this Agreement shall not be deemed to provide any evidence as to the meaning of any provision hereof or the intent
of the parties with respect thereto.

 

We May Execute this Agreement in
Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all
of which together shall constitute one and the same instrument. A telecopy signature of any party shall be considered to have the
same binding legal effect as an original signature.

 

Prevailing Party Rights. In
the event that any dispute among the parties to this Agreement should result in arbitration or litigation, the substantially prevailing
party in such dispute shall be entitled to recover from the losing party all fees, costs and expenses of enforcing any right of
such prevailing party under or with respect to this Agreement, including without limitation, such reasonable fees and expenses
of attorneys and accountants, which shall include, without limitation, all fees, costs and expenses of appeals and collection.

 

If the foregoing is in accordance with
your understanding, kindly confirm your acceptance and agreement by signing and returning the enclosed duplicate of this Agreement
that will thereupon constitute an agreement between us.

 

Accepted and approved this 17th day of June
2015.

 

 

By:
/s/ Robert S. Sand                              

Robert Sand,CEO

FBEC Worldwide, Inc.

 

 

By: /s/ Adam Heimann                           

Adam Heimann, Partner

MIDAM Ventures LLC

1522 SAN IGNACIO #3

CORAL GABLES, FL 33413

 

 

    	4

    	 

    

 

Exhibit A:

Tasks are listed in no specific order.

 

		·	Investors Relations & Public Relations for FBEC Worldwide Inc.

		·	Corporate / Ecommerce web development.

		·	Social media marketing for corporate & Ecommerce.

		·	Seek out & solidify online & offline retail / wholesale distribution for FBEC brands.

		·	Business Consulting

		·	Provide Coverage from Marijuanastocks.com & WolfofWeedStreet.com

 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00246-of-00352.parquet"}]]